Patent intelligence · US
US 9896664
Oncolytic rhabdovirus
Oncolytic rhabdovirus
Patent details — US 9896664
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 20, 2018
- Expiration
- Feb 15, 2038
- Applicant
- TURNSTONE LIMITED PARTNERSHIP
- Claims
- 21
- CPC classes
- A61K, A61K35/766, A61K35/768, A61K45/06
Quick answer
US 9896664 (Oncolytic rhabdovirus) is held by TURNSTONE LIMITED PARTNERSHIP. Status: granted. Granted Feb 20, 2018. Expires Feb 15, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TURNSTONE LIMITED PARTNERSHIP
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K35/766, A61K35/768, A61K45/06, A61P, A61P35/00
More from TURNSTONE LIMITED PARTNERSHIP
Related pharmaceutical patents in our USPTO index.
-
US 12310968
Chiral diaryl macrocycles and uses thereof
granted -
US 12252488
HPK1 antagonists and uses thereof
granted -
US 12215105
HPK1 antagonists and uses thereof
granted -
US 12187739
Diaryl macrocycle polymorph
granted -
US 12071442
Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
granted -
US 11981684
Macrocyclic compounds and uses thereof
granted -
US 11926625
HPK1 antagonists and uses thereof
granted -
US 11802292
Modified orthopoxvirus vectors
granted
Related coverage
Frequently asked questions
What is US patent 9896664?
US 9896664 (Oncolytic rhabdovirus) is held by TURNSTONE LIMITED PARTNERSHIP. Status: granted. Granted Feb 20, 2018. Expires Feb 15, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9896664?
TURNSTONE LIMITED PARTNERSHIP is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 40 pharmaceutical patents for this assignee.
When does US 9896664 expire?
Our index shows an expiration date of Feb 15, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.